Properties |
Information |
PhytoCAT-ID |
PhytoCAT-784 |
Phytochemical name or plant extracts |
Alizarin |
PMID |
22411621 |
Literature evidence |
Importantly, Alizarin had a significantly lower inhibitory activity on normal cells (IC(50) for MSC, 828.6 µg/ml), thereby revealing a selective activity towards malignant cells. |
IUPAC name |
1,2-dihydroxyanthracene-9,10-dione |
Phytochemicals’ class or type of plant extracts |
Quinone |
Source of phytochemicals or plant Extracts |
Rubia tinctorum |
|
Geographical availability |
Afghanistan, Albania, Cyprus, East Aegean Is., Greece, India, Iran, Iraq, Italy, Kazakhstan, Kirgizstan, Kriti, Krym, Lebanon-Syria, North Caucasus, Pakistan, Palestine, Sicilia, South European Russi, Tadzhikistan, Transcaucasus, Turkey, Turkey-in-Europe, Turkmenistan, Ukraine, Uzbekistan, Vietnam, West Himalaya, Xinjiang, Yugoslavia |
Plant parts |
Root |
Other cancers |
Breast cancer, Bone cancer |
Target gene or protein |
NA |
Gene or Protein evidence |
NA |
Target pathways |
NA |
IC50 |
62.1 µg/ml against MDA-MB-231 |
Potency |
We demonstrated that low dosages of Alizarin strongly inhibited the osteosarcoma (IC(50) for Saos-2, MG-63, and U-2 OS cells, 27.5, 29.0, and 69.9 µg/ml, respectively) and breast carcinoma (IC(50) for MDA-MB-231 cells, 62.1 µg/ml) cell proliferation in vitro. Importantly, Alizarin had a significantly lower inhibitory activity on normal cells (IC(50) for MSC, 828.6 µg/ml), thereby revealing a selective activity towards malignant cells. |
Cell line/ mice model |
MDA-MB-231 |
Additional information |
Furthermore, we found that Alizarin acted through the inhibition of ERK phosphorylation and cell cycle arrest in the S-phase.
Finally, Alizarin significantly and strongly impaired both osteosarcoma and breast cancer tumorigenesis. |
PubChem ID |
6293 |
Additional PMIDs |
15579325 15537303 17092687 34010709 22411621 |
Additional sources of information |
https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:765369-1 |
Safety |
NA |